Global Oligonucleotide Synthesis Global Market Report 2022: Featuring Agilent Technologies, CSBIO, Danaher, Kaneka & More


Dublin, Nov. 29, 2022 (GLOBE NEWSWIRE) -- The "Global Oligonucleotide Synthesis Market by Product (Drug, Synthesized Oligo (Primer), Reagents), Type (Custom, Predesigned), Application (Therapeutic (ASO, siRNA), Research (PCR, Sequencing, Diagnostics)), End-user (Pharma, CROS, CMOs), and Region - Forecast to 2027" report has been added to's offering.

The global oligonucleotide synthesis market is projected to reach USD 16.7 billion by 2027 from USD 7.7 billion in 2022, at a CAGR of 16.8% during the forecast period. Market growth can be attributed to the increasing ongoing clinical trials for oligonucleotide-based therapies for leading therapeutic areas such as oncology.

The primers segment will grow at the highest rate in the synthesized oligos market, by product

By product, the synthesized oligonucleotides market segment is divided into primers, probes, DNA oligos, RNA oligos, and other synthesized oligos such as BNA & LNA oligos. Primers are expected to show the highest growth over the forecast period owing to their wide applications in PCR, sequencing, gene synthesis, and cloning.

By therapeutic application, the antisense oligonucleotide-based therapies segment accounted for the largest share of the oligonucleotide synthesis market in 2021

The therapeutic application segment is further segmented into antisense oligonucleotide-based therapies, siRNA oligonucleotide-based therapies, and CpG oligonucleotide-based therapies. In 2021, antisense oligos accounted for the largest share of this segment as they form the basis of many therapies that are currently in clinical trials, thus boosting segment growth.

Danaher Corporation (US), Thermo Fisher Scientific, Inc. (US), Merck KGaA (Germany), LGC Limited (UK), Maravai Life Sciences (US), Agilent Technologies, Inc. (US), Eurofins Scientific (Germany), Kaneka Corporation (Japan), Biolegio B.V. (Netherlands), Biolytic Lab Performance Inc. (US), Microsynth AG (Switzerland), ATDBio Ltd. (UK), Twist Bioscience Corporation (US), Eton Bioscience, Inc. (US), CSBIO (US), Tag Copenhagen A/S (Denmark), Biogen Inc. (US), Sarepta Therapeutics, Inc. (US), Ionis Pharmaceuticals, Inc. (US), and Alnylam Pharmaceuticals, Inc. (US) are some of the major players operating in the market.

Asia-Pacific region will register a highest CAGR in the oligonucleotide synthesis market

The market for oligonucleotide synthesis in Asia-Pacific is anticipated to develop at the fastest rate during the forecast period. Growing R&D funding and research activity, increased product availability and decreased outsourcing costs are some of the factors that are likely to propel market growth.

Key Topics Covered:

1 Introduction

2 Research Methodology

3 Executive Summary

4 Premium Insights

5 Market Overview

6 Oligonucleotide Synthesis Market, by Product

7 Oligonucleotide Synthesis Market, by Application

8 Oligonucleotide Synthesis Market, by End-user

9 Oligonucleotide Synthesis Market, by Region

10 Competitive Landscape

11 Company Profiles

12 Appendix

Companies Mentioned

  • Agilent Technologies, Inc.
  • Alnylam Pharmaceuticals, Inc.
  • ATDBio Ltd.
  • Biocomma Limited
  • Biogen Inc.
  • Biolegio B.V
  • Biolytic Lab Performance Inc.
  • Danaher Corporation
  • Eton Bioscience, Inc.
  • Eurofins Scientific
  • Generi Biotech
  • Hangzhou Pharm & Chem Co. Ltd
  • Hongene Biotech Corporation
  • Ionis Pharmaceuticals, Inc.
  • Kaneka Corporation
  • LGC Limited
  • Maravai Life Sciences
  • Merck KGaA
  • Microsynth AG
  • Sarepta Therapeutics, Inc.
  • Tag Copenhagen A/S
  • Thermo Fisher Scientific Inc.
  • Tokyo Chemical Industry Co. Ltd.
  • Twist Bioscience Corporation

For more information about this report visit


Global Oligonucleotide Synthesis Market